. 2019 Jun 6;19(7):45. doi: 10.1007/s11910-019-0962-7

Table 5.

Summary of second-generation Tau PET tracers

Tracer	[¹⁸F]PBB3	[¹⁸F]GTP1	[¹⁸F]MK-6240	[¹⁸F]PI-2620	[¹⁸F]RO6958948 (RO-948)
					[¹¹C]RO6931643 (RO-643)
					[¹¹C]RO6924963 (RO-963)
Structural characteristics	¹⁸F-labelled PBB derivatives		Pyridine isoquinoline amine derivative
Preclinical study	-Higher signal-to-background ratio	-Rapid pharmacokinetics	-High affinity	-High affinity	-High affinity
	-Less off-target signals than [¹¹C]PBB3		-No off-target binding to MAO-A /MAO-B	-High selectivity over Aβ, MAO-A and MAO-B	-High selectivity over Aβ, MAO-A and MAO-B
	-Less off-target signals than [¹¹C]PBB3		-No off-target binding to MAO-A /MAO-B	-Low off-target binding	-High selectivity over Aβ, MAO-A and MAO-B
Clinical Human study	-Broader dynamic range compared to [¹¹C]PBB3		-Favourable pharmacokinetics	-No off-target binding in regions seen in first-generation tau tracers	-Favourable pharmacokinetics
	-No prominent off-target binding in the basal ganglia and thalamus		-Correlated well with neuropathological staging of NFTs		-High affinity
			-No off-target binding in the basal ganglia and choroid plexus		-High selectivity over Aβ, MAO-A and MAO-B
			-Mild tracer retention in the substantia nigra and meninges		-High signal-to-background ratio
References	[66•]	[56•]	[57•, 59, 60]	[62]	[63, 65•, 67]